Star is born with promise to deliver rare disease therapies

US biotech Star Therapeutics has emerged from stealth mode with $100 million in financing and the ambition to be an innovation engine for rare disease therapies.

San Francisco-based Star is applying expertise in rare diseases and antibody drug discovery to generate drug programs that target multiple diseases with a single therapy.

All of the company’s current drug programs represent first-in-class therapies and were internally generated, starting from early discovery efforts by its team.